Androgen receptor attenuation of Ad5 replication: Implications for the development of conditionally replication competent adenoviruses

Molecular Therapy

Volumn 15, Issue 8, 2007, Pages 1495-1503

  Höti, Naseruddin ^a   Li, Ying ^a   Chen, Chien Lun ^b   Chowdhury, Wasim H ^a   Johns, David C ^c   Xia, Qinghua ^a   Kabul, Arup ^a   Hsieh, Jer Tsong ^d   Berg, Michael ^e   Ketner, Gary ^e   Lupold, Shawn E ^a   Rodriguez, Ronald ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c JOHNS HOPKINS HOSPITAL   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; E1A PROTEIN; ONCOLYTIC VIRUS;

ADENOVIRUS; ARTICLE; CELL STRAIN LNCAP; CONTROLLED STUDY; GENE INDUCTION; GENE TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; INHIBITION KINETICS; MALE; MALIGNANT NEOPLASTIC DISEASE; ONCOLYTIC VIROTHERAPY; PROMOTER REGION; PROSTATE CANCER; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; TISSUE SPECIFICITY; TRANSCRIPTION INITIATION; TUMOR GROWTH; TUMOR XENOGRAFT; VIRAL GENE THERAPY; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ANIMALS; CELL LINE, TUMOR; GENETIC VECTORS; HUMANS; MALE; MICE; MICE, NUDE; ONCOGENE PROTEINS; PROSTATE; RECEPTORS, ANDROGEN; RECOMBINANT PROTEINS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34547131558     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300223     Document Type: Article

References (34)

1. DeWeese, TL, van der Poel, H, Li, S, Mikhak, B, Drew, R, Goemann, M et al. (2001). A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 61: 7464-7472.
2. Rodriguez, R, Schuur, ER, Lim, HY, Henderson, GA, Simons, JW and Henderson, DR (1997). Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 57: 2559-2563.
3. Chen, CD, Welsbie, DS, Tran, C, Baek, SH, Chen, R, Vessella, R et al. (2004). Molecular determinants of resistance to antiandrogen therapy. Nat Med 10: 33-39.
4. Zegarra-Moro, OL, Schmidt, LJ, Huang, H and Tindall, DJ (2002). Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 62: 1008-1013.
5. Ludlow, JW and Skuse, GR (1995). Viral oncoprotein binding to pRB, p107, p130, and p300. Virus Res 35: 113-121.
6. Mymryk, JS and Smith, MM (1997). Influence of the adenovirus 5 E1A oncogene on chromatin remodelling. Biochem Cell Biol 75: 95-102.
7. Frisch, SM and Mymryk, JS (2002). Adenovirus-5 E1A: Paradox and paradigm. Nat Rev Mol Cell Biol 3 441-452.
8. Chakravarti, D, LaMorte, VJ, Nelson, MC, Nakajima, T, Schulman, IG, Juguilon, H et al. (1996). Role of CBP/P300 in nuclear receptor signalling. Nature 383: 99-103.
9. Debes, JD, Schmidt, LJ, Huang, H and Tindall, DJ (2002). p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res 62: 5632-5636.
10. Aarnisalo, P, Palvimo, JJ and Janne, OA (1998). CREB-binding protein in androgen receptor-mediated signaling. Proc Natl Acad Sci USA 95 2122-2127.
11. Carette, JE, Graat, HC, Schagen, FH, Abou El Hassan, MA, Gerritsen, WR and van Beusechem, VW (2005). Replication-dependent transgene expression from a conditionally replicating adenovirus via alternative splicing to a heterologous splice-acceptor site. J Gene Med 7: 1053-1062.
12. Le, LP, Le, HN, Dmitriev, IP, Davydova, JG, Gavrikova, T, Yamamoto, S et al. (2006). Dynamic monitoring of oncolytic adenovirus in vivo by genetic capsid labeling. J Natl Cancer Inst 98: 203-214.
13. Ono, HA, Le, LP, Davydova, JG, Gavrikova, T and Yamamoto, M (2005). Noninvasive visualization of adenovirus replication with a fluorescent reporter in the E3 region. Cancer Res 65: 10154-10158.
14. Lie-A-Ling, M, Bakker, CT, Wesseling, JG and Bosma, PJ (2005). AdEasy-based cloning system to generate tropism expanded replicating adenoviruses expressing transgenes late in the viral life cycle. Gene Ther 12: 1347-1352.
15. van der Poel, HG, McCadden, J, Verhaegh, GW, Kruszewski, M, Ferrer, F, Schalken, JA et al. (2001). A novel method for the determination of basal gene expression of tissue-specific promoters: An analysis of prostate-specific promoters. Cancer Gene Ther 8: 927-935.
16. Dyer, BW, Ferrer, FA, Klinedinst, DK and Rodriguez, R (2000). A noncommercial dual luciferase enzyme assay system for reporter gene analysis. Anal Biochem 282: 158-161.
17. Korkmaz, CG, Fronsdal, K, Zhang, Y, Lorenzo, PI and Saatcioglu, F (2004). Potentiation of androgen receptor transcriptional activity by inhibition of histone deacetylation - rescue of transcriptionally compromised mutants. J Endocrinol 182: 377-389.
18. Watt, F, Martorana, A, Brookes, DE, Ho, T, Kingsley, E, O'Keefe, DS et al. (2001). A tissue-specific enhancer of the prostate-specific membrane antigen gene, FOLH1. Genomics 73: 243-254.
19. Veldscholte, J, Ris-Stalpers, C, Kuiper, GG, Jenster, G, Berrevoets, C, Claassen, E et al. (1990). A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173: 534-540.
20. Johns, DC, Marx, R, Mains, RE, O'Rourke, B and Marban, E (1999). Inducible genetic suppression of neuronal excitability. J Neurosci 19: 1691-1697.
21. Ylikomi, T, Wurtz, JM, Syvala, H, Passinen, S, Pekki, A, Haverinen, M et al. (1998). Reappraisal of the role of heat shock proteins as regulators of steroid receptor activity. Crit Rev Biochem Mol Biol 33: 437-466.
22. American Cancer Society (2006). Cancer Facts and Figures 2006.
23. Petrylak, DP, Tangen, CM, Hussain, MH, Lara, PN Jr., Jones, JA, Taplin, ME et al. (2004). Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520.
24. Matsubara, S, Wada, Y, Gardner, TA, Egawa, M, Park, MS, Hsieh, CL et al. (2001). A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Cancer Res 61: 6012-6019.
25. Hsieh, CL, Yang, L, Miao, L, Yeung, F, Kao, C, Yang, H et al. (2002). A novel targeting modality to enhance adenoviral replication by vitamin D(3) in androgen-independent human prostate cancer cells and tumors. Cancer Res 62: 3084-3092.
26. Freytag, SO, Khil, M, Stricker, H, Peabody, J, Menon, M, DePeralta-Venturina, M et al. (2002). Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 62: 4968-4976.
27. Doronin, K, Kuppuswamy, M, Toth, K, Tollefson, AE, Krajcsi, P, Krougliak, V et al. (2001). Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy. J Virol 75: 3314-3324.
28. Yu, DC, Chen, Y, Seng, M, Dilley, J and Henderson, DR (1999). The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res 59: 4200-4203.
29. Freytag, SO, Stricker, H, Pegg, J, Paielli, D, Pradhan, DG, Peabody, J et al. (2003). Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res 63: 7497-7506.
30. Small, EJ, Carducci, MA, Burke, JM, Rodriguez, R, Fong, L, van Ummersen, L et al. (2006). A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther 14: 107-117.
31. Hoti, N, Chowdhury, W, Hsieh, JT, Sachs, MD, Lupold, SE and Rodriguez, R (2006). Valproic Acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy. Mol Ther 14: 768-778.
32. Lu, S, Liu, M, Epner, DE, Tsai, SY and Tsai, MJ (1999). Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter. Mol Endocrinol 13: 376-384.
33. Okegawa, T, Li, Y, Pong, RC, Bergelson, JM, Zhou, J and Hsieh, JT (2000). The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy. Cancer Res 60: 5031-5036.
34. Fallaux, FJ, Bout, A, van der Velde, I, van den Wollenberg, DJ, Hehir, KM, Keegan, J et al. (1998). New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 9: 1909-1917.